Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists | Zendy

Shenping Liu | Zendy; Leslie Dakin | Zendy; Xing Li | Zendy; Jane M. Withka | Zendy; Parag V. Sahasrabudhe | Zendy; Wei Li | Zendy; Mary Ellen Banker | Zendy; Paul Balbo | Zendy; Suman Shanker | Zendy; Boris A. Chrunyk | Zendy; Zuojun Guo | Zendy; Jinshan M. Chen | Zendy; Jennifer A. Young | Zendy; Guoyun Bai | Zendy; Jeremy T. Starr | Zendy; Stephen W. Wright | Zendy; Joerg Bussenius | Zendy; Sheng Tan | Zendy; Ariamala Gopalsamy | Zendy; Bruce A. Lefker | Zendy; Fabien Vincent | Zendy; Lyn H. Jones | Zendy; Hua Xu | Zendy; Lise R. Hoth | Zendy; Kieran F. Geoghegan | Zendy; Xiayang Qiu | Zendy; Mark E. Bunnage | Zendy; Atli Thorarensen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists

Author(s) -

Shenping Liu,

Leslie Dakin,

Xing Li,

Jane M. Withka,

Parag V. Sahasrabudhe,

Wei Li,

Mary Ellen Banker,

Paul Balbo,

Suman Shanker,

Boris A. Chrunyk,

Zuojun Guo,

Jinshan M. Chen,

Jennifer A. Young,

Guoyun Bai,

Jeremy T. Starr,

Stephen W. Wright,

Joerg Bussenius,

Sheng Tan,

Ariamala Gopalsamy,

Bruce A. Lefker,

Fabien Vincent,

Lyn H. Jones,

Hua Xu,

Lise R. Hoth,

Kieran F. Geoghegan,

Xiayang Qiu,

Mark E. Bunnage,

Atli Thorarensen

Publication year - 2016

Publication title -

scientific reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.24

H-Index - 213

ISSN - 2045-2322

DOI - 10.1038/srep30859

Subject(s) - computational biology , binding site , bioinformatics , chemistry , computer science , stereochemistry , medicine , biology , biochemistry

Interleukin-17A (IL-17A) is a principal driver of multiple inflammatory and immune disorders. Antibodies that neutralize IL-17A or its receptor (IL-17RA) deliver efficacy in autoimmune diseases, but no small-molecule IL-17A antagonists have yet progressed into clinical trials. Investigation of a series of linear peptide ligands to IL-17A and characterization of their binding site has enabled the design of novel macrocyclic ligands that are themselves potent IL-17A antagonists.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research